

## DAFTAR PUSTAKA

- Al-Harithy, R.N., 2014. Common polymorphisms in the visfatin gene (NAMPT/PBEF1) influence visfatin-circulating levels in a Saudi population. *Life Sci.*, 11(10): 205–210.
- Antje, K., Bottcher, Y., Enigk, B., Kiess, W., Stumvoll, M., Kovacs, P., 2007. Effects of genetic variation in the visfatin gene ( PBEF1 ) on obesity, glucose metabolism, and blood pressure in children. *Metab. Clin. Exp.*, 56: 772–777.
- Arya, R., Blangero, J., Williams, K., Almasy, L., Dyer, T.D., Leach, R. J., O'Connel., *et al.*, 2002. Factors of insulin resistance syndrome-related phenotypes are linked to genetic locations on chromosomes 6 and 7 in nondiabetic Mexican-Americans. *Diabetes*, 51(3): 841–847.
- Babio, N., Ibarrola-Jurado, N., Bullo, M., Martinez-Gonzalez, M.A., Warnberg, J., Salaverria, I., Ortega-Calvo, M., *et al.*, 2012. White blood cell count as risk marker of developing metabolic syndrome and its components in the predimed study. *Plos ONE*. 8(3): e58354.
- Bermudez, B., Dahl, T. B., Medina, I., Groeneweg, M., Holm, S., Montserrat-de la Paz, S., 2013. Leucocytes overexpression of intracellular NAMPT attenuates atherosclerosis by regulating PPAR $\gamma$ -dependent monocytes differentiation and function. *Arterioscler Tromb Vasc Biol*, 37:1157-1167.
- Bo, M.S., Cheah, W.L., Lwin, S., New, T.M., Win, T.T., Aung, M., 2018. Understanding the relationship between atherogenic index of plasma and cardiovascular disease risk factors among staff of an University in Malaysia. *J. Nutr. Metab.* 2018: 1-6.
- Bosy-Westphal, A., Onur, S., Geisler, C., Wolf, A., Korth, O., Pfeuffer, M., Schrezenmeir, J., *et al.*, 2007. Common familial influences on clustering of metabolic syndrome traits with central obesity and insulin resistance: The Kiel obesity prevention study. *Int. J. Obes.*, 31(5): 784–790.
- Carson, C., Lawson, H.A., 2018. Epigenetics of metabolic syndrome. *Physiol. Genomics*, 50 (11): 947-955.
- Catalan, V., Gomez-Ambrosi, J., Rodriguez, A., Ramirez, B., Silva, C., Rotellar, F., Cienfuegos, J.A., *et al.*, 2011. Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. *Nutr. Metab. Cardiovasc. Dis.*, 21: 245-253.
- Chang, Y., Chang, D., Lin, K., Shin, S., Lee, Y., 2011. Visfatin in overweight /obesity, type 2 diabetes mellitus, insulin resistance, metabolic syndrome and cardiovascular diseases : a meta-analysis and systemic review. *Diabetes Metab. Res. Rev.*, 27: 515-527.
- Chen, Y., Chen, M., Wu, Z., Zhao, S., 2013. Ox-LDL induces ER stress and promotes the adipokines secretion in 3T3-L1 adipocytes. *PLoS ONE*, 8(11): 1–8.
- Dahl, T.B., Bermudez, B., Ranheim, T., Otterdal, K., Holm, S., Al-Biessen, E.,

- Halvorsen, B., *et al.*, 2012. Unraveling the role of nicotinamide phosphoribosyltransferase on lipids in atherosclerosis. *Clin. Lipidol.*, 7(6): 697-707.
- Dobiasova, M. dan Frohlich, J., 2001. The plasma parameter log (TG/HDL-C) as an atherogenic index: Correlation with lipoprotein particle size and esterification rate in apob-lipoprotein-depleted plasma (FERHDL). *Clin. Biochem.*, 34(7): 583-588.
- Dou, Q., Peng, Y., Zhou, B., Zhang, K., Lin, J., Dai, X., Zhang, L., *et al.*, 2015. Association of nicotinamide phosphoribosyltransferase (NAMPT) gene polymorphisms and of serum NAMPT levels with dilated cardiomyopathy in a Chinese population. *Int. J. Mol. Sci.*, 16(9): c22299-22318.
- Eckel, R.H., Grundy, S.M., Zimmet, P.Z., 2005. The metabolic syndrome. *Lancet*, 365(9468): 1415-1428.
- Favorgen, 2018. Manual procedure of genomic DNA extraction blood DNA mini/midi/maxi. diunduh dari [http://www.favorgen.com/products/nucleic\\_genomic\\_dna\\_extraction/blood\\_dna.html](http://www.favorgen.com/products/nucleic_genomic_dna_extraction/blood_dna.html).
- Ferrari, D.F., Rodrigues, J.A.L., Fernandes, I.A., Bueno Junior, C.R., 2016. Association between rs4730153 gene SNP and fasting glucose, triglyceride, HDL and body mass index levels in overweight Brazilian adults. *Int. J. Cardiol. Sci.*, 29(6): 471-476.
- Friebe, D., Loffler, D., Schonberg, M., Bernhard, F., Buttner, P., Landgraf, K., Kiess W., *et al.*, 2011. Impact of metabolic regulators on the expression of the obesity associated genes FTO and NAMPT in human preadipocytes and adipocytes. *PLoS ONE* 6(6):1-6.
- Galassi, A., Reynolds, K., He, J., 2006. Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. *Am. J. Med.*, 119: 812-819.
- Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., Kiess, W., 2015. Physiological and pathophysiological roles of NAMPT and NAD metabolism. *Nat. Rev. Endocrinol.*: 1-12 (advance online publication). Diunduh dari [www.nature.com/nrendo](http://www.nature.com/nrendo).
- Gouranton, E., Romier, B., Marcotrichino, J., Tourniaire, F., Astier, J., Peiretti, F., Landrier, J., *et al.*, 2014. Visfatin is involved in TNF  $\alpha$  -mediated insulin resistance via an NAD + / Sirt1 / PTP1B pathway in 3T3-L1 adipocytes. *Adipocytes*. 3(3): 180-189.
- Hector, J., Schwarzloh, B., Goehring, J., Strate, T.G., Hess, U.F., Deuretzbacher, G., Hansen-Algenstaedt, N., *et al.*, 2007. TNF- $\alpha$  alters visfatin and adiponectin levels in human fat. *Horm. Metab. Res.*, 39(4): 250-255.
- Henneman, P., Aulchenko, Y.S., Frants, R.R., Van Dijk, K.W., Oostra, B.A., Van Duijn, C.M., 2008. Prevalence and heritability of the metabolic syndrome and its individual components in a Dutch isolate: The Erasmus Rucphen Family study. *J. Med. Genet.*, 45(9): 572-577.
- Huang, T. dan Hu, F.B., 2015. Gene-environment interactions and obesity: recent

- developments and future directions. *BMC Med. Genomics*, 8(Suppl 1):4–9.
- Hui Jia, S., Li, Y., Parodo, J., Kapus, A., Fan, L., Rostein, O.D., *et al.*, 2004. Pre-B cell colony-enhancing factor inhibit neutrophil apoptosis in experimental inflammation and clinical sepsis. *J. Clin. Invest.*, 113 (9) : 1318-1327
- Jin, L.W., Zheng, S.B., Zhou, Z.H., Pan, S.F., Zheng, Y., 2016. Correlation between polymorphisms in the visfatin gene and its expression in the serum and coronary artery calcification. *Genet. Mol. Res.*, 15(2):1–10.
- Kaur, J., 2014. A Comprehensive review on metabolic syndrome. *Cardiol. Res. Pract.*, Volume 2014, Article ID 943162: 1-21.
- Kolovou, G.D., Anagnostopoulou, K.K., Salpea, K.D., Mikhailidis, D.P., 2007. The prevalence of metabolic syndrome in various populations. *Am. J. Med. Sci.*, 333(6): 362–371.
- Kover, K., Tong, P.Y., Watkins, D., Clements, M., Sthno-Bittel, L., Novikova, L., Bittel, D. *et al.*, 2013. Expression and regulation of NAMPT in human islets. *PLOSOne*, 8(3): 1–11.
- Kementerian Kesehatan Republik Indonesia, 2016. Peraturan menteri kesehatan Republik Indonesia Nomor 25 tahun 2016 tentang rencana aksi nasional kesehatan lanjut usia tahun 2016.
- Kementerian Kesehatan Republik Indonesia, 2017. Hasil utama riset kesehatan dasar (RISKESDAS) 2018.
- Lai, A., Chen, W., Helm, K. 2013. Effects of visfatin gene polymorphism rs4730153 on exercise-induced weight loss of obese children and adolescents of Han Chinese. *Int. J. Biol. Sci.*, 9(1): 16-21.
- Lajunen, T.K., Purhonen, A., Haapea, M., Ruokonen, A., Puukka, K., Hartikainen, A., Savolainen M.J., *et al.*, 2010. Full-length visfatin levels are associated with inflammation in women with polycystic ovary syndrome. *Eur J Clin Invest.* 42 (3): 321-28.
- Larrad, M.T.M., Anchuelo A.C., Fernandez, P., Barba, M.P., Redondo, Y.I., Rios, M.S., 2016. Obesity and cardiovascular risk: Variations in visfatin gene can modify the obesity associated cardiovascular risk. Results from the Segovia population based-study Spain. *PLoS ONE*, 11(5): 1–11.
- Lee, S., Chang, H., Sung, J., Kim, K., Shin, S., Cho, I., 2014. The impact of obesity on subclinical coronary atherosclerosis according to the risk of cardiovascular diseases. *Obesity*, 22:1262-1768.
- Lemeshow, S. Hosmer D.W, Kalr, J., K.Lwanga., 1990. Part 1: 'Statistical methods for sample size determination', adequacy of sample size in health studies. WHO 9:11.
- Li, S., Wang, C., Li, K., Li, L., Tian, M., Xie, J., Yang, M., 2016. NAMPT knockdown attenuates atherosclerosis and promotes reverse cholesterol transport in ApoE KO mice with high-fat- induced insulin resistance. *Sci. Rep.*, 6: 1–14.
- Martin C.J.H, Watson R.R., Preedy V.R., 2013. Nutrition and diet in menopause. Springer; New York. 3; 18-33.
- Moller, D.E. dan Kaufman, K.D., 2005. Metabolic syndrome: A clinical and molecular

- perspective. *Annu. Rev. Med.*, 56(1): 45–62.
- Monteiro, R., dan Azevedo, I., 2010. Review article: Chronic inflammation in obesity and the metabolic syndrome. *Hindawi publishing corporation*. 2010: 1-10.
- Moschen, A.R., Gerner, R.R., Tilg, H., 2010. Pre-B cell colony enhancing factor/NAMPT/visfatin in inflammation and obesity-related disorders. *Curr. Pharm. Des.*, 16(17): 1913–20.
- Moy, F.M., Bulgiba, A., 2010. The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnostic metabolic syndrome among Malays in Kuala Lumpur. *BMC Public Health*. 10:678.
- NCBI, 2018. NAMPT nicotinamide phosphorybosyltransferase (Homo sapiens (human)). Diunduh dari <https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=10135>.
- Nielsen, K.N., Peics, J., Ma, T., Karavaeva, I., Dall, M., Chubanava, S., Basse, A.L., et al., 2018. NAMPT-mediated NAD D biosynthesis is indispensable for adipose tissue plasticity and development of obesity. *Mol. Metab.*, 11: 178-188.
- Nussbaum, R.L., McInnes, R.R., Willard, H.F., 2007. Thompson & Thompson Genetics in medicine. Elsevier. 7<sup>th</sup> Ed: 207-226.
- Ooi, S.Q., Chan, R.M. E., Chan, Poh, L.K.S., Yoke, K.Y., Heng, C.K., 2013. Visfatin and its genetic variants are associated with obesity-related morbidities and cardiometabolic risk in severely obese children. *Pediatric obesity* 9: 81-91.
- Ooi, D.S.Q., Ong, S.G., Heng, C.K., Loke, K.Y., Lee, Y.S., 2016. In-vitro function of upstream visfatin polymorphisms that are associated with adverse cardiometabolic parameters in obese children. *BMC Genomics*. BMC Genomics 17(1): 1–7.
- Povel, C.M., Boer, J.M.A., Feskens, E.J.M., 2011. Shared genetic variance between the features of the metabolic syndrome: Heritability studies. *Mol. Gen. Metab.*, 104(4): 666–669.
- Pradhan, A.D., 2014. Sex difference in the metabolic syndrome: implication for cardiovascular health in women. *Clin Chem.*, 60(1): 44-52.
- Ranasinghe, P., Mathangasinghe, Y., Jayawardena, R., Hills, A.P., Misra, A., 2017. Prevalence and trends of metabolic syndrome among adults in the asia-pacific region : a systematic review. *BMC Public Health* 17:101.
- Revollo, J.R., Korner, A., Mills, K.F., Satoh, A., Wang, T, Garten, A., Dasgupta, B., et al., 2007. Nampt/PBEF/Visfatin Reglucosates Insulin Secretion in  $\beta$  Cells as a Systemic NAD Biosynthetic Enzyme. *Cell Metab.*, 6(5): 363–375.
- Roche, 2016. Manual procedure of Glucose-HK, Trigliceride, Total Cholesterol-Gen2, and HDL-Precipitant Gen.4. Germany.
- Rodriguez, C.P., Gonzales, M.C., Aguilar-Salinas C.A., Najera-Medina, O., 2018. Peripheral Lymphocytes, obesity and metabolic syndrome in young adults: An immunometabolism study. *Metabolic Syndrome and related disorders*.
- Romacho, T., Azcutia, V., Vazquez-Bella, M., Matesanz, N., Cercas, E., Nevado, J., Carraro, R., et al., 2009. Extracellular PBEF/NAMPT/visfatin activates pro-

- inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. *Diabetologia*, 52(11): 2455–2463.
- Rong, J., Chu, M., Xing, B., Zhu, L., Wang, S., Tao, T., Zhao, Y., Jiang, L., 2015. Variation in the PBEF gene are associated with body mass index: a population-based study in northern China. *Meta Gene.*, 6:65-68.
- Shen, S. W., Lu, Y., Li, F., Yang, C., Feng, Y., Li, H., *et al.*, 2018. Atherogenic index of plasma is an effective index for estimating abdominal obesity. *Lipids Health Dis.*, 17(1): 4–9.
- Sommer, G., Garten, A., Petzold, S., Beck-Sickinger, A., G., Bluher, M., Stumvoll, M., 2008. Visfatin/PBEF/NAMPT: structure, reglukosation and potential function of novel adipokine. *Clin. Sci.*, 115: 13-32.
- Sommer, G., Kralisch, S., Kloting, N., Kamprad, M., Schorrock, K., Kratzsch, J., Tonjes, A., *et al.*, 2010. Visfatin is a positive reglukosator of MCP-1 in human adipocytes in vitro and in mice in vivo. *Obesity*, 18(8): 1486–1492.
- St-onge, M., Gallagher, D., 2010. Body composition change with aging: The cause or the result of alteration in metabolic rate and macronutrient oxidation. *Nutrition*. 26(2): 152-155.
- Suhaema dan Masthalina, H., 2015. Pola konsumsi dengan terjadinya sindrom metabolik di Indonesia. *J. Kes. Mas.*, 9(4): 340–347.
- Sun, K., Liu, J., Ning, G., 2012. Active Smoking and Risk of Metabolic Syndrome: A Meta-Analysis of Prospective Studies. *Plos One.*, 7(10): 1-9.
- Teran-Garcia, M., Bouchard, C., 2007. Genetic of metabolic syndrome. *App. Physiol. Nutr. Metab.*, 32: 89-114.
- Tokunaga, A., Miura, A., Okauchi, Y., Segawa, K., Fukuhara, A., Okita, K., *et al.*, 2008. The -1535 Promoter Variant of The Visfatin Gene Is Associated with Serum Triglyceride and HDL-cholesterol Levels in Japanese Subjects. *Endocrine Journal* 55(1):205–212.
- Wang, L.S., Yan, J.J., Tang, N.P., Zhu, J., Wang, Y.S., Wang, Q.M., *et al.*, 2011. A polymorphism in the visfatin gene promoter is related to decreased plasma levels of inflammatory markers in patients with coronary artery disease. *Mol. Biol. Rep.*, 38: 819-825.
- Wang, Y., Gao, W., Li, H., Wang, Z., Zhu, J., Zhao, H., Yan, J., *et al.*, 2012. Mechanistic insights into the link between visfatin gene C-1535T polymorphism and coronary artery disease: an in vitro study. *Mol. Cell Biochem.*, 363: 315-322.
- Williams, J. S., Brawn, S. M. dan Conlin, P. R., 2009. Blood pressure measurement, *N. Engl. J. Med.*, 360(e6):1–4.
- World Health Organization, 2000. Section 4 : guide to physical measurements (step 2) overview', STEPwise approach to surveillance of chronic non-communicable disease manual. WHO STEPS Surveillance.
- World Health Organization, 2008. Waist circumference and waist-hip ratio report of a WHO expert consultation. WHO Library Cataloguing in Publication Data :6-8.

- Yan, J., Tang N, Tang, j., Wang, M., Wang, Q, Zhu, J., Yang, Z., *et al.*, 2010. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. *Clin. Chim. Act.*, 411:26–30.
- Zhang, K., Zhou, B., Zhang, P., Zhang, Z., Chen, P., Pu, Y., Song, Y., *et al.*, 2014. Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group. *Tumor. Biol.*, 35(5): 4031-40
- Zhong, M., Tan, H., Gong, H., Wang, S., Zhang, Y., Zhang W., 2008. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. *Clin. Endocrinol.*, 69: 878-884.
- Zhou, F., Pan, Y., Huang, Z., Jia, Y., Zhao, X., Chen, Y., 2013. Visfatin induces cholesterol accumulation in macrophage through up-regulation of scavenger receptor-A and CD-36. *Cell stress Chaperones*, 18: 643-652.